Lennox Gastaut Syndrome: Emerging Gene Therapy and Precision Medicine Approaches
Lennox Gastaut Syndrome (LGS) is a
severe childhood-onset epilepsy characterized by multiple seizure types, cognitive impairment, and resistance to conventional antiepileptic drugs. Recent advances in gene therapy and precision medicine are offering new hope for patients with this debilitating condition.
Gene therapy aims to address the underlying genetic causes of LGS by delivering functional copies of defective genes or modulating gene expression in neural tissue. Viral vectors and novel gene-editing techniques such as CRISPR-Cas9 are being investigated to restore normal neuronal function, reduce seizure frequency, and improve developmental outcomes.
Precision medicine approaches also focus on tailoring treatment to an individual’s genetic and molecular profile. Comprehensive genomic analyses identify specific mutations contributing to LGS, enabling targeted therapies that are more effective and less toxic than conventional antiepileptics. Biomarkers are being explored to predict treatment response, monitor disease progression, and optimize medication regimens.
In addition to pharmacological interventions, neurostimulation devices and dietary…


What sets the College of Contract Management apart is its emphasis on real-world application. Courses often include case studies and practical assessments. These elements help students build confidence in handling professional challenges.